An interventional study of Riboflavin in Quality of Life, sponsored by dsm-firmenich Switzerland AG. Completed at 1 site in Ireland. Open to participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by dsm-firmenich Switzerland AG (part of dsm-firmenich) · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this intervention study (clinical trial) is to investigate the effect of colon-delivered Riboflavin (vitamin B2) on the faecal microbial composition and diversity in older healthy subjects (50 -70 years of age)
dsm-firmenich Switzerland AG is the lead sponsor of 10 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has a skin condition likely to interfere with skin assessments (e.g., eczema, dermatitis, any open skin wounds, reactive and sensitive skin).
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks
Dietary Supplement: Riboflavin
Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks
Dietary Supplement: Riboflavin
Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks
Dietary Supplement: Riboflavin
One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks
Dietary Supplement: Riboflavin
Colon delivered vitamin B2 (Riboflavin) for 12 weeks
Faecal microbial composition
Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 12
Time frame: from baseline to 12 weeks
Alpha diversity
Alpha diversity (Observed, Chao Index, Simpson Index, Shannon Index) at baseline and week 12.
Time frame: from baseline to 12 weeks
Beta diversity
Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 12
Time frame: week 0 to week 12
Faecal microbial metabolites fatty acid content at baseline and week 12
Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 12
Time frame: from baseline to 12 weeks
Acetate, Propionate and Butyrate
Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 12.
Time frame: baseline and week 12
Intestinal inflammation
Intestinal barrier integrity as assessed by sCD14 at baseline and at week 12
Time frame: from baseline to 12 weeks
Intestinal barrier integrity
Oxidative stress level measured as free thiol content in blood at baseline and at week 12
Time frame: from baseline to 12 weeks
Oxidative stress in blood
Oxidative stress level measured as free thiol content in blood at baseline and at week 12
Time frame: from baseline to 12 weeks
Inflammatory status in blood
Systemic inflammation measured as high sensitive C reactive protein (hs-CRP) in blood at baseline and at week 12.
Time frame: from baseline to 12 weeks
Gastrointestinal symptoms
Gastrointestinal symptoms as assessed by Gastrointestinal Symptom Rating Scale (GSRS).The GSRS is a 15 items questionnaire combined into five symptom clusters i.e Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.(GSRS) at baseline and at week 12.
Time frame: from baseline to 12 weeks
health-related quality of life
Quality of life as assessed by short form survey-36 (SF-36) questionnaires at baseline and at week 12. The SF-36 is a self-administered questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as a physical component summary and a mental component summary. The norm data is 0-100, and the health-related quality of life increases as the scores increase.
Time frame: from baseline to 12 weeks
Stool consistency
Stool consistency (Bristol Stool Scale), as reported in the daily eDiary app (at baseline and week 12). Participants will identify each bowel movement 'type' using the Bristol Stool Scale (Type 1 = hard stool difficult to pass \[classified as severe constipation\]; Type 7 = watery, entirely liquid stool \[classified as severe diarrhea\]). 'Normal' stool is considered to be Types 3 and 4; and Types 6 and 7 would be considered to suggest mild and severe diarrhea, respectively.
Time frame: from baseline to 12 weeks
Stool frequency
Stool frequency, as reported in the daily eDiary app (at baseline and week 12).
Time frame: from baseline to 12 weeks
Systemic vitamin status
The concentration of B vitamins in blood at baseline
Time frame: from baseline to 12 weeks
Faecal physiological pH and redox
Faecal physiological parameters measured as pH and redox potential at baseline and at week 12.
Time frame: from baseline to 12 weeks
Faecal microbial composition at week 4
Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 4.
Time frame: from baseline to 4 weeks
Alpha diversity at week 4
Alpha diversity measured as Observed, Chao Index, Simpson Index, Shannon Index at baseline and Week 4.
Time frame: baseline to Week 4.
Beta diversity at week 4
Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 4
Time frame: week 0 to week 4
Microbial metabolites at week 4
Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 4.
Time frame: from baseline to 4 weeks
Acetate, Propionate and Butyrate at week 4
Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 4.
Time frame: week 0 to week 4
Skin barrier integrity
Skin barrier integrity measured as trans-epidermal water loss (TEWL) g/m²/h at baseline and at week 12.
Time frame: from baseline to 12 weeks
Skin hydration
Skin hydration measured using corneometry from 0 (no water at all) to 120 (on water) at baseline and at week 12.
Time frame: from baseline to 12 weeks
Objective skin-health
Objective skin-health assessment completed by the participant using Likert scale (from not at al to very much) at baseline and at week 12.
Time frame: from baseline to 12 weeks
Ran from Dec 2022 to primary completion in Jul 2023, 6 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Riboflavin
dsm-firmenich Switzerland AG →